These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 36107013)
1. Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis. Zhang C; Liu Y; Wang Y; Ge X; Jiao T; Yin J; Wang K; Li C; Guo S; Xie X; Xie C; Nan F J Med Chem; 2022 Oct; 65(19):13452-13472. PubMed ID: 36107013 [TBL] [Abstract][Full Text] [Related]
2. Discovery of 4-aminophenylacetamide derivatives as intestine-specific farnesoid X receptor antagonists for the potential treatment of nonalcoholic steatohepatitis. Chen C; Zhang B; Tu J; Peng Y; Zhou Y; Yang X; Yu Q; Tan X Eur J Med Chem; 2024 Jan; 264():115992. PubMed ID: 38043493 [TBL] [Abstract][Full Text] [Related]
3. Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice. Gu M; Zhao P; Zhang S; Fan S; Yang L; Tong Q; Ji G; Huang C Br J Pharmacol; 2019 Apr; 176(7):847-863. PubMed ID: 30635917 [TBL] [Abstract][Full Text] [Related]
4. Restraint stress promotes nonalcoholic steatohepatitis by regulating the farnesoid X receptor/NLRP3 signaling pathway. Yang F; Lv XT; Lin XL; Wang RH; Wang SM; Wang GE Acta Biochim Biophys Sin (Shanghai); 2023 Dec; 55(12):1961-1971. PubMed ID: 37997375 [TBL] [Abstract][Full Text] [Related]
5. Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling. Zhai Y; Zhou W; Yan X; Qiao Y; Guan L; Zhang Z; Liu H; Jiang J; Liu J; Peng L Phytomedicine; 2022 Dec; 107():154444. PubMed ID: 36155217 [TBL] [Abstract][Full Text] [Related]
6. Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis. Hu YB; Liu XY; Zhan W Drug Des Devel Ther; 2018; 12():2213-2221. PubMed ID: 30038487 [TBL] [Abstract][Full Text] [Related]
7. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis. Wu W; Liu X; Peng X; Xue R; Ji L; Shen X; Chen S; Gu J; Zhang S Biochem Biophys Res Commun; 2014 May; 448(1):50-5. PubMed ID: 24747563 [TBL] [Abstract][Full Text] [Related]
8. The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice. Wang XX; Xie C; Libby AE; Ranjit S; Levi J; Myakala K; Bhasin K; Jones BA; Orlicky DJ; Takahashi S; Dvornikov A; Kleiner DE; Hewitt SM; Adorini L; Kopp JB; Krausz KW; Rosenberg A; McManaman JL; Robertson CE; Ir D; Frank DN; Luo Y; Gonzalez FJ; Gratton E; Levi M J Biol Chem; 2022 Nov; 298(11):102530. PubMed ID: 36209823 [TBL] [Abstract][Full Text] [Related]
9. An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease. Gonzalez FJ; Jiang C; Patterson AD Gastroenterology; 2016 Nov; 151(5):845-859. PubMed ID: 27639801 [TBL] [Abstract][Full Text] [Related]
10. Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis. Mo C; Xu X; Zhang P; Peng Y; Zhao X; Chen S; Guo F; Xiong Y; Chu XJ; Xu X J Med Chem; 2023 Jul; 66(14):9363-9375. PubMed ID: 37424079 [TBL] [Abstract][Full Text] [Related]
11. Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice. Li J; Liu C; Zhou Z; Dou B; Huang J; Huang L; Zheng P; Fan S; Huang C Phytother Res; 2021 Jun; 35(6):3351-3364. PubMed ID: 33784797 [TBL] [Abstract][Full Text] [Related]
12. Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist. Moon AN; Briand F; Breyner N; Song DK; Madsen MR; Kim H; Choi K; Lee Y; Namkung W Biomed Pharmacother; 2024 Apr; 173():116331. PubMed ID: 38428307 [TBL] [Abstract][Full Text] [Related]
13. INT-767 improves histopathological features in a diet-induced Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205 [TBL] [Abstract][Full Text] [Related]
14. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal. Schmitt J; Kong B; Stieger B; Tschopp O; Schultze SM; Rau M; Weber A; Müllhaupt B; Guo GL; Geier A Liver Int; 2015 Apr; 35(4):1133-1144. PubMed ID: 25156247 [TBL] [Abstract][Full Text] [Related]
15. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182 [TBL] [Abstract][Full Text] [Related]
16. Sodium cholate ameliorates nonalcoholic steatohepatitis by activation of FXR signaling. Pan L; Yu Z; Liang X; Yao J; Fu Y; He X; Ren X; Chen J; Li X; Lu M; Lan T Hepatol Commun; 2023 Feb; 7(2):e0039. PubMed ID: 36706173 [TBL] [Abstract][Full Text] [Related]
17. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis. Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173 [TBL] [Abstract][Full Text] [Related]
18. Soyasaponin A Xiong F; Zheng Z; Xiao L; Su C; Chen J; Gu X; Tang J; Zhao Y; Luo H; Zha L Mol Nutr Food Res; 2021 Jul; 65(14):e2100067. PubMed ID: 34047448 [TBL] [Abstract][Full Text] [Related]
19. Glycine-β-muricholic acid antagonizes the intestinal farnesoid X receptor-ceramide axis and ameliorates NASH in mice. Jiang J; Ma Y; Liu Y; Lu D; Gao X; Krausz KW; Desai D; Amin SG; Patterson AD; Gonzalez FJ; Xie C Hepatol Commun; 2022 Dec; 6(12):3363-3378. PubMed ID: 36196594 [TBL] [Abstract][Full Text] [Related]
20. Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome. Gay MD; Cao H; Shivapurkar N; Dakshanamurthy S; Kallakury B; Tucker RD; Kwagyan J; Smith JP Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]